# Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

> **NCT00590785** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (estimated)

## Conditions studied

- High Risk
- Breast Cancer
- Positive Nodes
- Cyclophosphamide
- Doxorubicin

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** G-CSF
- **DRUG:** tamoxifen
- **DRUG:** ciprofloxacin

## Key facts

- **NCT ID:** NCT00590785
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-08-13
- **Primary completion:** 1997-06-10
- **Final completion:** 2015-01-13
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00590785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00590785, "Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00590785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*